Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Viruses · 2024
DOI: 10.3390/v16121899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Carlo Smirne und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 256 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics. Despite these advancements, recent studies have reported that even after sustained virologic response (SVR), individuals with advanced liver disease/cirrhosis at the time of DAA treatment may still face risks of HCC occurrence or recurrence. Based on this premise, this review tries to shed light on the multiple mechanisms that establish a tumorigenic environment, first, during chronic HCV infection and then, after eventual viral eradication by DAAs. Furthermore, it reviews evidence reported by recent observational studies stating that the use of DAAs is not associated with an increased risk of HCC development but rather, with a significantly lower chance of liver cancer compared with DAA-untreated patients. In addition, it seeks to provide some practical guidance for clinicians, helping them to manage HCC surveillance of patients who have achieved SVR with DAAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
- Internal Medicine Unit, Maggiore della Carità Hospital, 28100 Novara, Italy.
- Laboratory of Molecular Virology, Maggiore della Carità Hospital, 28100 Novara, Italy.
- Clinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, Italy.
- Emergency Medicine Department, Michele e Pietro Ferrero Hospital, 12060 Verduno, Italy.
- Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London SW7 2AZ, UK.
ORCID-Profile: Carlo Smirne, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Rosalba Minisini, Stelvio Tonello, Davide D'Onghia, Silvia Martini, Luigi Maria Fenoglio, Alessandro Maria Berton, Alessia Ciancio, Mario Pirisi
Zitieren
APA
Smirne, C., Crobu, M. G., Landi, I., Vercellino, N., Apostolo, D., Pinato, D. J., Vincenzi, F., Minisini, R., Tonello, S., D'Onghia, D., Ottobrelli, A., Martini, S., Bracco, C., Fenoglio, L. M., Campanini, M., Berton, A. M., Ciancio, A., & Pirisi, M. (2024). Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?. Viruses. https://doi.org/10.3390/v16121899
Vancouver
Smirne C, Crobu MG, Landi I, Vercellino N, Apostolo D, Pinato DJ, et al. Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?. Viruses. 2024. doi:10.3390/v16121899
BibTeX
@article{Smirne2024,
author = {Smirne, Carlo and Crobu, Maria Grazia and Landi, Irene and Vercellino, Nicole and Apostolo, Daria and Pinato, David James and Vincenzi, Federica and Minisini, Rosalba and Tonello, Stelvio and D'Onghia, Davide and Ottobrelli, Antonio and Martini, Silvia and Bracco, Christian and Fenoglio, Luigi Maria and Campanini, Mauro and Berton, Alessandro Maria and Ciancio, Alessia and Pirisi, Mario},
title = {Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121899}
}
EUVIMED